Currently, there are 211.70M common shares owned by the public and among those 173.37M shares have been available to trade.
The company’s stock has a 5-day price change of -16.45% and -27.29% over the past three months. OSCR shares are trading 64.26% year to date (YTD), with the 12-month market performance up to 86.48% higher. It has a 12-month low price of $7.50 and touched a high of $23.79 over the same period. OSCR has an average intraday trading volume of 4.08 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.48%, -10.36%, and -13.73% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Oscar Health Inc (NYSE: OSCR) shares accounts for 61.53% of the company’s 211.70M shares outstanding.
It has a market capitalization of $3.72B and a beta (3y monthly) value of 1.64. The earnings-per-share (ttm) stands at -$0.06. The company has a debt-to-equity ratio at 0.26. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.62% over the week and 7.92% over the month.
Earnings per share for the fiscal year are expected to increase by 106.62%, and 831.45% over the next financial year.
Looking at the support for the OSCR, a number of firms have released research notes about the stock. Jefferies stated their Underperform rating for the stock in a research note on Dec-11-24, with the firm’s price target at $12. BofA Securities coverage for the Oscar Health Inc (OSCR) stock in a research note released on November 06, 2024 offered a Underperform rating with a price target of $13.50. UBS was of a view on October 07, 2024 that the stock is Neutral, while Piper Sandler gave the stock Overweight rating on June 26, 2024, issuing a price target of $25. Robert W. Baird on their part issued Outperform rating on May 30, 2024.
